Cancer and thrombosis: An increasingly important association

Supportive Care in Cancer

Volumn 16, Issue 3, 2008, Pages 223-228

  Korte, Wolfgang ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Deep venous thrombosis; Embolism; Venous thromboembolism

Indexed keywords

COUMARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTICLE; CANCER PATIENT; CANCER RESEARCH; DECISION MAKING; HYPERCOAGULABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 41049087602     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0376-y     Document Type: Article

References (62)

1. Trousseau A (1865) Phlegmasia alba dolens. Clin Med Hotel-Dieu Paris 3:654-712
2. Prandoni P, Piccioli A, Girolami A (1999) Cancer and venous thromboembolism: an overview. Haematologica 84:437-445
3. Falanga A (2005) Thrombophilia in cancer. Semin Thromb Hemost 31:104-110
4. Tallman MS, Kwaan HC (2004) Intravascular clotting activation and bleeding in patients with hematologic malignancies. Rev Clin Exp Hematol 8:E1
5. Pereira J, Phan T (2004) Management of bleeding in patients with advanced cancer. Oncologist 9:561-570
6. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488
7. Kirwan CC, Nath E, Byrne GJ, McCollum CN (2003) Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ 327:597-598
8. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7
9. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850
10. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 342:1953-1958
11. Cook N, Thomas DM (2002) Retrospective survey of unselected hospital patients with and without cancer comparing outcomes following venous thromboembolism. Intern Med J 32:437-444
12. Johnson MJ, Walker ID, Sproule MW, Conkie J (1999) Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 21:51-54
13. Ambrus JL, Ambrus CM, Mink IB, Pickren JW (1975) Causes of death in cancer patients. J Med 6:61-64
14. Ogren M, Bergqvist D, Wahlander K, Eriksson H, Sternby NH (2006) Trousseau's syndrome-what is the evidence? A population-based autopsy study. Thromb Haemost 95:541-545
15. Franchini M, Montagnana M, Targher G, Manzato F, Lippi G (2007) Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 24:29-38
16. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13:2870-2875
17. Mulder AB, Zwaveling JH, Smid WM, Maring JK, van Ginkel RJ, Girbes AR, Schraffordt Koops H, van der Meer J (1996) Augmented procoagulant activity in cancer patients, treated with recombinant interferon-gamma in addition to recombinant tumor necrosis factor-alpha and melphalan. Thromb Haemost 76:897-901
18. Falanga A, Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173-182
19. Nawroth PP, Stern DM (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740-745
20. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63:3403-3412
21. Rickles FR, Falanga A (2001) Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102:V215-V224
22. Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294
23. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737
24. Prandoni P (1997) Antithrombotic strategies in patients with cancer. Thromb Haemost 78:141-144
25. Samama MM (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160:3415-3420
26. Duggan C, Marriott K, Edwards R, Cuzick J (2003) Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 21:3588-3593
27. Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N (2006) Effect of Factor V Leiden and prothrombin G20210->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 98:904-910
28. Ravin AJ, Edwards RP, Krohn MA, Kelley JR, Christopherson WA, Roberts JM (2002) The factor V Leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 100:1285-1289
29. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P, Hiller E (2002) Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 94:3120-3126
30. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M (1998) Venous thromboembolism and cancer. Lancet 351:1077-1080
31. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173
32. Piccioli A, Lensing AW, Prins MH, Falanga A, Scannapieco GL, Ieran M, Cigolini M, Ambrosio GB, Monreal M, Girolami A, Prandoni P (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2:884-889
33. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L (1996) Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 125:785-793
34. Goldhaber SZ, Dricker E, Buring JE, Eberlein K, Godleski JJ, Mayer RJ, Hennekens CH (1987) Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients. Am Heart J 114:1432-1435
35. Lin J, Proctor MC, Varma M, Greenfield LJ, Upchurch GR Jr., Henke PK (2003) Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg 37:976-983
36. Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G, Nguyen NP (2004) Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 10:7238-7243
37. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutierrez V, Vaquero C (1999) Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30:283-292
38. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153
39. Kovacs MJ, Levine MN, Keeney M, Mackinnon KM, Lee AY (2005) Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thromb Haemost 93:1185-1188
40. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:401S-428S
41. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975-980
42. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913-930
43. Bergqvist D, ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 84:1099-1103
44. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729-1735
45. Cunningham MS, White B, O'Donnell J (2006) Prevention and management of venous thromboembolism in people with cancer: a review of the evidence. Clin Oncol (R Coll Radiol) 18:145-151
46. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S-400S
47. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, Slabber C, Fountzilas G, Garin A, Abecasis NG, Baronius W, Steger GG, Sudhoff T, Giorgetti C, Reichardt P (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 17:289-296
48. Levine MN, Lee AY, Kakkar AK (2003) From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 1:1456-1463
49. Green D, Hull RD, Brant R, Pineo GF (1992) Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339:1476
50. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L (2000) Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16:815-824
51. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266-1271
52. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 22:1944-1948
53. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129
54. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135
55. Akl E, van Doormaal F, Barba M, Kamath G, Kim S, Kuipers S, Middeldorp S, Yosuico V, Dickinson H, Schunemann H (2007) Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev:CD006652
56. Siragusa S, Arcara C, Malato A, Anastasio R, Valerio MR, Fulfaro F, Lo Coco L, Grimaudo S, Bajardi G, Abbadessa V, Gebbia N (2005) Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol 16:iv136-iv139
57. Schwartz RN (2005) Considerations and challenges with existing treatments for thrombosis in cancer patients. Am J Health Syst Pharm 62:S7-S9
58. Seeholzer N, Thurlimann B, Koberle D, Hess D, Korte W (2007) Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. Blood Coagul Fibrinolysis 18:415-423
59. Johnson MJ (1997) Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 11:306-312
60. Johnson MJ, Sherry K (1997) How do palliative physicians manage venous thromboembolism? Palliat Med 11:462-468
61. Noble SI, Finlay IG (2005) Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19:197-201
62. Noble SI, Nelson A, Turner C, Finlay IG (2006) Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 332:577-580